6-K 1 c257-20191220x6k.htm 6-K Form 6K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of December 2019

 

Commission File Number: 001-37710

 

 

HUTCHISON CHINA MEDITECH LIMITED

(Translation of registrant’s name into English)

 

 

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒             Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

HUTCHISON CHINA MEDITECH LIMITED

 

Form 6-K

 

EXHIBIT INDEX

 

Exhibit No.Description

 

Exhibit 99.1Press release relating to new drug application for surufatinib in non-pancreatic neuroendocrine tumors granted priority review in China

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

HUTCHISON CHINA MEDITECH LIMITED

 

 

 

 

 

 

 

By:

/s/ Johnny Cheng

 

Name:

Johnny Cheng

 

Title:

Chief Financial Officer

 

 

Date: December 20, 2019

3